Prof Meletios Dimopoulos, Prof Pieter Sonneveld and Prof Heinz Ludwig discuss several new issues that were highlighted during the 13th International Myeloma Workshop in Paris, including the need to evaluate a more stringent definition of complete response (CR) in light of recent increases in the depth of CR seen with new regimens. Prof Sonneveld discusses the experience gained from CML in this area and the group discuss bone remodelling and the impact of bortezomib (Velcade) on osteoblast activity.

Professor Meletious Dimopoulos – University Athens, Greece
Professor Jesús San Miguel - University Hospital of Salamanca, Spain
Professor Pieter Sonneveld - Erasmus University Rotterdam, Netherlands
Professor Heinz Ludwig - Wilhelminenspital, Center for Oncology and Hematology, Vienna, Austria

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).